Help us determine the optimal timing of an experimental treatment for SOD1 ALS, and whether it can delay clinical onset

Recruiting participants

Study Name
Biogen ATLAS Trial
Biogen (sponsor). Academic Lead: Michael Benatar, MD, PhD.
Study Type
Interventional (double-blind and open-label phases)
Eligible Population
Part A (Natural History Run-In)
  • Age 18+
  • Carrier of a protocol-defined SOD1 mutation
  • Clinically pre-symptomatic for ALS
  • Plasma neurofilament light (NfL) level below protocol-defined threshold at time of screening
Study Purpose/Goals
To evaluate whether pre-symptomatic initiation of tofersen can delay the emergence of clinically manifest ALS and/or slow decline in function after emergence of clinically manifest ALS.

Up to 6.5 years of participation

  • Screening: up to 42 days
  • Part A (Natural History Run-In): up to 6.5 years
  • Treatment: up to 2 years
  • Open label extension


  • Medical history and medication review
  • Drug dosing (as applicable)
  • Blood, urine and CSF collection
  • Neurological exam
  • Electrocardiogram
  • Physical exam
  • Surveys
  • Breathing test

Join our family - together, we can change the course of this disease.

Join our family

Together, we can change the course of this disease.